Saamya Biotech (India) Limited Stock

Saamya Biotech (India) Limited is an India-based biotechnology company. The Company's principal activity is trading of active pharmaceutical ingredients (API). The Company is engaged in the business of research and development of biotechnology products. The Company focuses on manufacturing and marketing of biopharmaceuticals and recombinant protein products of medical and industrial fields. The Company focuses on setting up of manufacturing facilities with an aggregate installed capacity of 342 kilograms per annum of bulk APIs of biopharmaceuticals. The Company also focuses on manufacturing Daunomycin, Hyaluronic acid (Pharma Grade), Tacrolimus, Rapamycin, Cyclosporin A, Probiotics, Lysergic Acid, Mycophenolic Acid, Clavulenic Acid, Vancomycin, Co-Enzyme Q10, Interferon B and Monoclonal Antibodies (anti-cancer). The Company intends to manufacture biopharmaceuticals in its plant located in Hyderabad, India.